Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cariprazine - Mapi Pharma

Next Previous
Drug Profile

Cariprazine - Mapi Pharma

Alternative Names: Cariprazine Depot - Mapi Pharma

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mapi Pharma
  • Class
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Bipolar disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 17 Sep 2025 Mapi Pharma and an undisclosed large pharmaceutical company enteres into the development agreement for the development of cariprazine
  • 17 Sep 2025 Mapi Pharma has patent protection for "Depot system comprising glatiramer acetate" in the US, Brazil, the European Union, Mexico, Spain, China, Japan, Canada, Australia and patent pending application in Poland, Lithuania, Hungary, Portugal, Croatia, Turkey, Slovenia, San Marino, Hong Kong and Cyprus (Prior to September 2025)
  • 17 Sep 2025 Mapi Pharma plans a phase III of cariprazine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top